Thus, intra-uterine installation of therapeutic compounds might be a promising strategy to improve neurodevelopmental outcomes in MCT8 deficiency, although this is limited to a very small group of patients who are diagnosed before birth. Here, SLC16A2 is linked to hyperinsulinemic hypoglycemia, familial, 4.